Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
about
Direct amination of γ-halo-β-ketoesters with anilines.YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases.
P2860
Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@en
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@nl
type
label
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@en
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@nl
prefLabel
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@en
Potent, selective, and orally ...... tituted dihydrofuropyrimidine.
@nl
P2093
P356
P1476
Potent, selective, and orally ...... stituted dihydrofuropyrimidine
@en
P2093
Antonio G Dipasquale
Cristina Lewis
Cuong Q Ly
Daniel F Ortwine
Elizabeth Blackwood
Frederick Cohen
Huifen Chen
Jennifer A Epler
Jiansheng Wu
Jim Nonomiya
P304
P356
10.1021/JM200215Y
P407
P577
2011-04-15T00:00:00Z